Bio-Techne Q2 2025 Earnings Report
Key Takeaways
Bio-Techne reported a 9% increase in second-quarter revenue to $297.0 million, driven by strong organic growth in both the Protein Sciences and Diagnostics & Spatial Biology segments. GAAP EPS increased to $0.22, and adjusted EPS rose to $0.42. The company also highlighted improved biopharma end-market conditions and a focus on profitability, resulting in a 30.1% adjusted operating margin.
Organic revenue increased by 9% to $297.0 million.
GAAP EPS was $0.22, up from $0.17 year-over-year.
Adjusted EPS reached $0.42, compared to $0.40 in the prior year.
Protein Sciences segment saw 8% organic growth, while Diagnostics & Spatial Biology grew by 12% organically.
Bio-Techne
Bio-Techne
Bio-Techne Revenue by Segment
Forward Guidance
No specific forward guidance was provided in the release.
Revenue & Expenses
Visualization of income flow from segment revenue to net income